| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0022 | 1 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.0022 | 1 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | -0.0044 | 1 |
| mRNA | NSC 74859 | CTRPv2 | pan-cancer | AAC | -0.0022 | 1 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | -0.0019 | 1 |
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | 0.0019 | 1 |